Zusammenfassung
Background and aims. The nonsystemic steroid budesonide has been used to treat active ileocecal and ileocolonic Crohn's disease (CD). This study investigated the optimal budesonide dose using a pH-dependent release formulation. The goal of treatment was the remission of CD (CDAI <150) within 6 weeks of treatment. Patients and methods. The study was of randomized, double-blind, dose-finding ...
Zusammenfassung
Background and aims. The nonsystemic steroid budesonide has been used to treat active ileocecal and ileocolonic Crohn's disease (CD). This study investigated the optimal budesonide dose using a pH-dependent release formulation. The goal of treatment was the remission of CD (CDAI <150) within 6 weeks of treatment. Patients and methods. The study was of randomized, double-blind, dose-finding design. Patients with active CD ileocolitis without steroid pretreatment were treated with 3x2 mg (n=39), 3x3 mg (n=33), or 3x6 mg (n=32) oral pH-modified released budesonide daily. Results. The remission rates after 6 weeks were 36% with 3x2 mg, 55% with 3x3 mg, and 66% with 3x6 mg. Significantly more patients were in remission while treated with 3x 6mg than with 3x2 mg budesonide/day. Subgroup analyses revealed that patients with high disease activity (CDAI greater than or equal to 300) or ileocolonic disease with disease manifestation distal to the transverse colon responded better to the highest budesonide dose. Conclusion. Oral pH-modified released budesonide shows a dose-dependent effectiveness in patients with active ileocolonic CD. In the majority of patients 9 mg budesonide per day is sufficient. However, in patients with highly active disease or ileal disease with distal colonic manifestation higher doses of budesonide could increase the therapeutic response.
Altmetric